Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexaria Bioscience Corp WT (LEXXW)

Lexaria Bioscience Corp WT (LEXXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 710 K
  • Annual Income, $ -11,900 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/13/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0009 +33.33%
on 01/13/26
0.0296 -95.95%
on 12/15/25
-0.0268 (-95.71%)
since 12/12/25
3-Month
0.0009 +33.33%
on 01/13/26
0.0700 -98.29%
on 11/13/25
-0.0376 (-96.91%)
since 10/13/25
52-Week
0.0009 +33.33%
on 01/13/26
0.8000 -99.85%
on 01/15/25
-0.6488 (-99.82%)
since 01/13/25

Most Recent Stories

More News
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Lexaria Announces $2 Million Registered Direct Offering of Common Stock

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Lexaria's Human GLP-1 Study #5 Begins Dosing

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria executing a triple-pronged strategy in obesity and diabetes

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Pursuing the world's first-ever orally-dosed liraglutide

LEXXW : 0.0012 (-77.36%)
LEXX : 0.7588 (+3.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar